Tags

Type your tag names separated by a space and hit enter

The role of anti-CGRP antibodies in the pathophysiology of primary headaches.
Neurol Sci. 2017 May; 38(Suppl 1):31-35.NS

Abstract

Calcitonin gene-related peptide (CGRP), a potent vasodilator and pain-signaling neuropeptide, is a validated therapeutic target for migraine and cluster headache. Four anti-CGRP monoclonal antibodies (mAbs) have been developed, representing the first specific, mechanism-based, migraine prophylactic treatment. CGRP mAbs demonstrated good efficacy coupled to excellent tolerability and safety in 5 phase II clinical trials. Notably, CGRP mAbs induced complete migraine remission in a patients' subset. To date, more than 20 phase III trials using CGRP mAbs for of episodic and chronic migraine and cluster headache prevention are ongoing. Future investigations will shed light on migraine endophenotypes predictive of good CGRP mAbs responsiveness and provide answers on their long-term cardiovascular safety.

Authors+Show Affiliations

Headache and Pain Unit, Department of Neurological, Motor and Sensorial Sciences, IRCCS San Raffaele Pisana, Via della Pisana 235, 00163, Rome, Italy. piero.barbanti@sanraffaele.it.Headache and Pain Unit, Department of Neurological, Motor and Sensorial Sciences, IRCCS San Raffaele Pisana, Via della Pisana 235, 00163, Rome, Italy.Headache and Pain Unit, Department of Neurological, Motor and Sensorial Sciences, IRCCS San Raffaele Pisana, Via della Pisana 235, 00163, Rome, Italy.Headache and Pain Unit, Department of Neurological, Motor and Sensorial Sciences, IRCCS San Raffaele Pisana, Via della Pisana 235, 00163, Rome, Italy.Department of Human Sciences and Quality of Life Promotion, San Raffaele Roma Open University, Rome, Italy.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

28527063

Citation

Barbanti, Piero, et al. "The Role of anti-CGRP Antibodies in the Pathophysiology of Primary Headaches." Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, vol. 38, no. Suppl 1, 2017, pp. 31-35.
Barbanti P, Aurilia C, Fofi L, et al. The role of anti-CGRP antibodies in the pathophysiology of primary headaches. Neurol Sci. 2017;38(Suppl 1):31-35.
Barbanti, P., Aurilia, C., Fofi, L., Egeo, G., & Ferroni, P. (2017). The role of anti-CGRP antibodies in the pathophysiology of primary headaches. Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 38(Suppl 1), 31-35. https://doi.org/10.1007/s10072-017-2907-8
Barbanti P, et al. The Role of anti-CGRP Antibodies in the Pathophysiology of Primary Headaches. Neurol Sci. 2017;38(Suppl 1):31-35. PubMed PMID: 28527063.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The role of anti-CGRP antibodies in the pathophysiology of primary headaches. AU - Barbanti,Piero, AU - Aurilia,Cinzia, AU - Fofi,Luisa, AU - Egeo,Gabriella, AU - Ferroni,Patrizia, PY - 2017/5/21/entrez PY - 2017/5/21/pubmed PY - 2018/3/9/medline KW - CGRP KW - Headache KW - Migraine KW - Monoclonal CGRP antibodies KW - Treatment SP - 31 EP - 35 JF - Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology JO - Neurol Sci VL - 38 IS - Suppl 1 N2 - Calcitonin gene-related peptide (CGRP), a potent vasodilator and pain-signaling neuropeptide, is a validated therapeutic target for migraine and cluster headache. Four anti-CGRP monoclonal antibodies (mAbs) have been developed, representing the first specific, mechanism-based, migraine prophylactic treatment. CGRP mAbs demonstrated good efficacy coupled to excellent tolerability and safety in 5 phase II clinical trials. Notably, CGRP mAbs induced complete migraine remission in a patients' subset. To date, more than 20 phase III trials using CGRP mAbs for of episodic and chronic migraine and cluster headache prevention are ongoing. Future investigations will shed light on migraine endophenotypes predictive of good CGRP mAbs responsiveness and provide answers on their long-term cardiovascular safety. SN - 1590-3478 UR - https://www.unboundmedicine.com/medline/citation/28527063/The_role_of_anti_CGRP_antibodies_in_the_pathophysiology_of_primary_headaches_ L2 - https://link.springer.com/10.1007/s10072-017-2907-8 DB - PRIME DP - Unbound Medicine ER -